

Cathee Till

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5650999/publications.pdf>

Version: 2024-02-01

14
papers

581
citations

1040056

9
h-index

1058476

14
g-index

14
all docs

14
docs citations

14
times ranked

1101
citing authors

#	ARTICLE	IF	CITATIONS
1	Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. <i>Journal of Clinical Oncology</i> , 2016, 34, 3014-3022.	1.6	170
2	“When Offered to Participate”: A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2021, 113, 244-257.	6.3	116
3	Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927. <i>Journal of Clinical Oncology</i> , 2015, 33, 1910-1917.	1.6	83
4	Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 2710-2717.	1.6	61
5	Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials. <i>Journal of Clinical Oncology</i> , 2016, 34, 4338-4344.	1.6	46
6	Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). <i>Breast Cancer Research and Treatment</i> , 2018, 172, 603-610.	2.5	37
7	Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial. <i>Cancer</i> , 2016, 122, 2332-2340.	4.1	20
8	Association between body mass index and response to duloxetine for aromatase inhibitor-associated musculoskeletal symptoms in SWOG S1202. <i>Cancer</i> , 2019, 125, 2123-2129.	4.1	18
9	Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1208-1215.	6.3	16
10	Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 455-463.	2.5	5
11	Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial. <i>Frontiers in Oncology</i> , 2021, 11, 808715.	2.8	4
12	Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial. <i>Cancer Prevention Research</i> , 2020, 13, 521-530.	1.5	2
13	Predictors of Pain Reduction in Trials of Interventions for Aromatase Inhibitor-Associated Musculoskeletal Symptoms. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab087.	2.9	2
14	History of Diabetes and Survival Outcome Among Participants 65 Years or Older in SWOG Clinical Trials. <i>JCO Clinical Cancer Informatics</i> , 2017, 1, 1-12.	2.1	1